199 related articles for article (PubMed ID: 28883469)
1. Characteristics of newly diagnosed COPD patients treated with triple inhaled therapy by general practitioners: a real world Italian study.
Di Marco F; Santus P; Terraneo S; Peruzzi E; Muscianisi E; Ripellino C; Pegoraro V
NPJ Prim Care Respir Med; 2017 Sep; 27(1):51. PubMed ID: 28883469
[TBL] [Abstract][Full Text] [Related]
2. GOLD 2017 treatment pathways in 'real life': An analysis of the DACCORD observational study.
Worth H; Buhl R; Criée CP; Kardos P; Lossi NS; Vogelmeier CF
Respir Med; 2017 Oct; 131():77-84. PubMed ID: 28947047
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β
Ferguson GT; Darken P; Ballal S; Siddiqui MK; Singh B; Attri S; Holmgren U; de Nigris E
Adv Ther; 2020 Jun; 37(6):2956-2975. PubMed ID: 32335859
[TBL] [Abstract][Full Text] [Related]
4. Triple inhaled therapy in COPD patients: determinants of prescription in primary care.
Vetrano DL; Zucchelli A; Bianchini E; Cricelli C; Piraino A; Zibellini M; Ricci A; Onder G; Lapi F
Respir Med; 2019; 154():12-17. PubMed ID: 31202120
[TBL] [Abstract][Full Text] [Related]
5. Prescription Patterns of New Use of Fixed-Dose Combination Inhalers in Patients with Chronic Obstructive Pulmonary Disease: Long-Acting β2 Agonists Plus Long-Acting Muscarinic Antagonists versus Long-Acting β2 Agonists Plus Inhaled Corticosteroids.
Liao PA; Pan SW; Chen CY; Deng CY; Dong YH
Int J Chron Obstruct Pulmon Dis; 2023; 18():553-563. PubMed ID: 37069844
[TBL] [Abstract][Full Text] [Related]
6. Determinants of initial inhaled corticosteroid use in patients with GOLD A/B COPD: a retrospective study of UK general practice.
Chalmers JD; Tebboth A; Gayle A; Ternouth A; Ramscar N
NPJ Prim Care Respir Med; 2017 Jun; 27(1):43. PubMed ID: 28663549
[TBL] [Abstract][Full Text] [Related]
7. Role of Long-Acting Muscarinic Antagonist/Long-Acting β
Petite SE
Ann Pharmacother; 2017 Aug; 51(8):696-705. PubMed ID: 28410560
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Long-Acting Beta
Samp JC; Joo MJ; Schumock GT; Calip GS; Pickard AS; Lee TA
Pharmacotherapy; 2017 Apr; 37(4):447-455. PubMed ID: 28226405
[TBL] [Abstract][Full Text] [Related]
9. The reasons for triple therapy in stable COPD patients in Japanese clinical practice.
Miyazaki M; Nakamura H; Takahashi S; Chubachi S; Sasaki M; Haraguchi M; Terai H; Ishii M; Fukunaga K; Tasaka S; Soejima K; Asano K; Betsuyaku T;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1053-9. PubMed ID: 26082629
[TBL] [Abstract][Full Text] [Related]
10. Respiratory pharmacotherapy use in patients newly diagnosed with chronic obstructive pulmonary disease in a primary care setting in the UK: a retrospective cohort study.
Wurst KE; Shukla A; Muellerova H; Davis KJ
COPD; 2014 Sep; 11(5):521-30. PubMed ID: 24945236
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy.
Mapel D; Laliberté F; Roberts MH; Sama SR; Sundaresan D; Pilon D; Lefebvre P; Duh MS; Patel J
Int J Chron Obstruct Pulmon Dis; 2017; 12():1825-1836. PubMed ID: 28684905
[TBL] [Abstract][Full Text] [Related]
12. Long-acting inhaled therapy (beta-agonists, anticholinergics and steroids) for COPD: a network meta-analysis.
Kew KM; Dias S; Cates CJ
Cochrane Database Syst Rev; 2014 Mar; 2014(3):CD010844. PubMed ID: 24671923
[TBL] [Abstract][Full Text] [Related]
13. Open triple therapy for chronic obstructive pulmonary disease: Patterns of prescription, exacerbations and healthcare costs from a large Italian claims database.
Calabria S; Ronconi G; Dondi L; Piccinni C; Pedrini A; Esposito I; Pistelli R; Martini N
Pulm Pharmacol Ther; 2020 Apr; 61():101904. PubMed ID: 32092473
[TBL] [Abstract][Full Text] [Related]
14. Management of COPD in the UK primary-care setting: an analysis of real-life prescribing patterns.
Price D; West D; Brusselle G; Gruffydd-Jones K; Jones R; Miravitlles M; Rossi A; Hutton C; Ashton VL; Stewart R; Bichel K
Int J Chron Obstruct Pulmon Dis; 2014; 9():889-904. PubMed ID: 25210450
[TBL] [Abstract][Full Text] [Related]
15. Adherence to current guidelines for chronic obstructive pulmonary disease (COPD) among patients treated with combination of long-acting bronchodilators or inhaled corticosteroids.
Asche CV; Leader S; Plauschinat C; Raparla S; Yan M; Ye X; Young D
Int J Chron Obstruct Pulmon Dis; 2012; 7():201-9. PubMed ID: 22500120
[TBL] [Abstract][Full Text] [Related]
16. Effects of inhaled corticosteroids /long-acting agonists in a single inhaler versus inhaled corticosteroids alone on all-cause mortality, pneumonia, and fracture in chronic obstructive pulmonary disease: A nationwide cohort study 2002-2013.
Cho KH; Kim YS; Linton JA; Nam CM; Choi Y; Park EC
Respir Med; 2017 Sep; 130():75-84. PubMed ID: 29206637
[TBL] [Abstract][Full Text] [Related]
17. Comparative Effectiveness and Safety of Different Types of Inhaled Long-Acting β
Wang MT; Lai JH; Huang YL; Liou JT; Cheng SH; Lin CW; Pan HY; Hsu YJ; Tsai CL
Chest; 2021 Oct; 160(4):1255-1270. PubMed ID: 34023320
[TBL] [Abstract][Full Text] [Related]
18. Overuse of long-acting β
Brunton SA; Hogarth DK
Postgrad Med; 2023 Nov; 135(8):784-802. PubMed ID: 38032494
[TBL] [Abstract][Full Text] [Related]
19. Triple inhaled therapy for chronic obstructive pulmonary disease.
Montuschi P; Malerba M; Macis G; Mores N; Santini G
Drug Discov Today; 2016 Nov; 21(11):1820-1827. PubMed ID: 27452453
[TBL] [Abstract][Full Text] [Related]
20. Dual combination therapy versus long-acting bronchodilators alone for chronic obstructive pulmonary disease (COPD): a systematic review and network meta-analysis.
Oba Y; Keeney E; Ghatehorde N; Dias S
Cochrane Database Syst Rev; 2018 Dec; 12(12):CD012620. PubMed ID: 30521694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
